Concordia International Corp. (NASDAQ: CXRX) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Concordia International Corp. to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.

Profitability

This table compares Concordia International Corp. and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concordia International Corp. -269.97% -83.96% -0.62%
Concordia International Corp. Competitors -3,612.23% -53.37% -8.67%

Valuation and Earnings

This table compares Concordia International Corp. and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Concordia International Corp. $677.25 million $326.58 million -0.03
Concordia International Corp. Competitors $7.78 billion $2.46 billion 1.04

Concordia International Corp.’s peers have higher revenue and earnings than Concordia International Corp.. Concordia International Corp. is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Concordia International Corp. has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Concordia International Corp.’s peers have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Concordia International Corp. and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concordia International Corp. 5 1 0 0 1.17
Concordia International Corp. Competitors 944 3795 6014 164 2.49

Concordia International Corp. currently has a consensus price target of $8.00, suggesting a potential upside of 561.16%. As a group, “Pharmaceuticals” companies have a potential upside of 25.59%. Given Concordia International Corp.’s higher probable upside, equities analysts plainly believe Concordia International Corp. is more favorable than its peers.

Institutional & Insider Ownership

9.1% of Concordia International Corp. shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Concordia International Corp. peers beat Concordia International Corp. on 9 of the 12 factors compared.

About Concordia International Corp.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Concordia International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International Corp. and related companies with MarketBeat.com's FREE daily email newsletter.